CN112203657A - 患有经典法布里病的患者的治疗 - Google Patents

患有经典法布里病的患者的治疗 Download PDF

Info

Publication number
CN112203657A
CN112203657A CN201980024335.8A CN201980024335A CN112203657A CN 112203657 A CN112203657 A CN 112203657A CN 201980024335 A CN201980024335 A CN 201980024335A CN 112203657 A CN112203657 A CN 112203657A
Authority
CN
China
Prior art keywords
migalastat
salt
patient
effective amount
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980024335.8A
Other languages
English (en)
Chinese (zh)
Inventor
杰伊·巴斯
埃尔弗里达·本杰明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112203657(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CN112203657A publication Critical patent/CN112203657A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980024335.8A 2018-02-06 2019-02-06 患有经典法布里病的患者的治疗 Pending CN112203657A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
US62/626,992 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Publications (1)

Publication Number Publication Date
CN112203657A true CN112203657A (zh) 2021-01-08

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024335.8A Pending CN112203657A (zh) 2018-02-06 2019-02-06 患有经典法布里病的患者的治疗

Country Status (20)

Country Link
US (1) US20210038579A1 (https=)
EP (2) EP4316589A3 (https=)
JP (2) JP2021512896A (https=)
KR (1) KR20200128675A (https=)
CN (1) CN112203657A (https=)
AR (1) AR114392A1 (https=)
AU (2) AU2019217603A1 (https=)
DK (1) DK3749308T3 (https=)
ES (1) ES2969263T3 (https=)
FI (1) FI3749308T3 (https=)
HR (1) HRP20240025T1 (https=)
HU (1) HUE064761T2 (https=)
LT (1) LT3749308T (https=)
PL (1) PL3749308T3 (https=)
PT (1) PT3749308T (https=)
RS (1) RS65103B1 (https=)
SI (1) SI3749308T1 (https=)
SM (1) SMT202400027T1 (https=)
TW (2) TWI869336B (https=)
WO (1) WO2019157056A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
US20150238474A1 (en) * 2006-05-16 2015-08-27 Amicus Therapeutics, Inc. Methods for Treatment of Fabry Disease
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
KR102004114B1 (ko) * 2016-03-22 2019-07-26 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238474A1 (en) * 2006-05-16 2015-08-27 Amicus Therapeutics, Inc. Methods for Treatment of Fabry Disease
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. P. GERMAIN等: "Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat" *
R. GIUGLIANI等: "A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects" *

Also Published As

Publication number Publication date
SMT202400027T1 (it) 2024-03-13
JP2021512896A (ja) 2021-05-20
HUE064761T2 (hu) 2024-04-28
ES2969263T3 (es) 2024-05-17
WO2019157056A8 (en) 2020-12-03
DK3749308T3 (da) 2024-01-22
RS65103B1 (sr) 2024-02-29
EP4316589A3 (en) 2024-04-24
SI3749308T1 (sl) 2024-03-29
WO2019157056A1 (en) 2019-08-15
AU2019217603A1 (en) 2020-09-24
EP3749308A1 (en) 2020-12-16
JP2024026080A (ja) 2024-02-28
CA3090499A1 (en) 2019-08-15
KR20200128675A (ko) 2020-11-16
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
US20210038579A1 (en) 2021-02-11
TWI869336B (zh) 2025-01-11
EP3749308B1 (en) 2023-10-25
AR114392A1 (es) 2020-09-02
LT3749308T (lt) 2024-02-12
EP4316589A2 (en) 2024-02-07
PT3749308T (pt) 2024-01-25
TW201944998A (zh) 2019-12-01
AU2025200074A1 (en) 2025-01-30
PL3749308T3 (pl) 2024-03-25
TW202537622A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
JP7784398B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
KR102631805B1 (ko) 신장 손상을 갖는 파브리 환자를 치료하는 방법
AU2025217396A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
KR102790184B1 (ko) 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
CN112203657A (zh) 患有经典法布里病的患者的治疗
KR102004114B1 (ko) Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
JP2025131572A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
JP2024161361A (ja) 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
JP2025128105A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2026016375A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
CN111278438A (zh) 治疗具有肾损害的法布里患者的方法
HK40044440A (en) Treatment of patients with classic fabry disease
HK40039916A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40085360A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40031708A (en) Methods of treating fabry patients having renal impairment
HK40073744A (en) Methods of treating fabry disease in patients having renal impairment
HK40044013A (en) Use of migalastat for treating fabry disease in pregnant patients
HK40007037A (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044440

Country of ref document: HK